Mind the gap in kidney care: translating what we know into what we do
DOI:
https://doi.org/10.52786/isu.a.94Keywords:
Chronic kidney disease, equity, kidney care, public health, World Kidney DayAbstract
Historically, it takes an average of 17 years to move new treatments from clinical evidence to daily practice. Given the highly effective treatments now available to prevent or delay kidney disease onset and progression, this is far too long. The time is now to narrow the gap between what we know and what we do. Clear guidelines exist for the prevention and management of common risk factors for kidney disease, such as hypertension and diabetes, but only a fraction of people with these conditions worldwide are diagnosed, and even fewer are treated to target. Similarly, the vast majority of people living with kidney disease are unaware of their condition, because in the early stages it is often silent. Even among patients who have been diagnosed, many do not receive appropriate treatment for kidney disease. Considering the serious consequences of kidney disease progression, kidney failure, or death, it is imperative that treatments are initiated early and appropriately. Opportunities to diagnose and treat kidney disease early must be maximized beginning at the primary care level. Many systematic barriers exist, ranging from patient to clinician to health systems to societal factors. To preserve and improve kidney health for everyone everywhere, each of these barriers must be acknowledged so that sustainable solutions are developed and implemented without further delay.
References
Jager KJ, Kovesdy C, Langham R, Rosenberg M, Jha V, Zoccali C. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Kidney Int 2019;96:1048-50.
Institute for Health Metrics and Evaluation (IHME). GBD compare data visualization [Internet]. [cite 2023 Nov 18]. Available from: http://vizhub.health- data.org/gbd-compare
Luyckx VA, Tonelli M, Stanifer JW. Stanifer, The global burden of kidney disease and the sustainable development goals. Bull World Health Organ 2018;96:414-22D.
International Society of Nephrology. ISN Global Kidney Health Atlas, 3rd ed [Internet]. [cited 2023 Nov 18]. Available from: https://www.theisn.org/initiatives/global-kidney-health-atlas/
GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2020;395:709-33.
Vanholder R, Annemans L, Brown E, Gansevoort R, Gout-Zwart JJ, Lameire N, et al. Reducing the costs of chronic kidney disease while delivering quality health care: a call to action. Nat Rev Nephrol 2017;13 393-409.
Nguyen-Thi HY, Le-Phuoc TN, Phat, NT, Van DT, Lethi TT, Le NDT, et al. The economic burden of chronic kidney disease in Vietnam. Health Serv Insights 2021;14:117863211036011.
US Renal Data System. Healthcare expenditures for persons with CKD [Internet]. [cited 2023 Nov 18]. Available from: https://usrds-adr.niddk.nih. gov/2023/chronic-kidney-disease/6-healthcare-expenditures-for-persons-with-ckd
Kidney Health Australia. Transforming Australia’s kidney health: a call to action for early detection and treatment of chronic kidney disease [Internet]. [cited 2024 Jan 16]. Available from: https://kidney.org.au/uploads/resources/Changing-the-CKD-landscape-Economic-benefits-of-early-detection-and-treatment.pdf
Ke C, Liang J, Liu M, Liu S, Wang C. Burden of chronic kidney disease and its risk-attributable burden in 137 low-and middle-income countries, 1990-2019: results from the global burden of disease study 2019. BMC Nephrol 2022;23:17.
Gregg EW, Buckley J, Ali MK, Davies J, Flood D, Mehta R, et al. Improving health outcomes of people with diabetes: target setting for the WHO Global Diabetes Compact. Lancet 2023;401:1302-12.
Geldsetzer P, Manne-Goehler J, Marcus ME, Ebert C, Zhumadilov Z, Wesseh CS, et al. The state of hypertension care in 44 low-income and middle-income countries: a cross-sectional study of nationally representative individual-level data from 1.1 million adults. Lancet 2019 ;394:652-62.
Chu L, Bhogal SK, Lin P, Steele A, Fuller M, Ciaccia A, et al. AWAREness of Diagnosis and Treatment of Chronic Kidney Disease in Adults With Type 2 Diabetes (AWARE-CKD in T2D). Can J Diabetes 2022;46:464-72.
Levin A, Tonelli M, Bonventre J, Coresh J, Donner JA, Fogo AB, et al. Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. Lancet 2017;390:1888-917.
Stengel B, Muenz D, Tu C, Speyer E, de Pinho NA, Combe C, et al. Adherence to the Kidney Disease: Improving Global Outcomes CKD guideline in nephrology practice across countries. Kidney Int Rep 2021;6:437-48.
Chu CD, Chen MH, McCulloch CE, Powe N, Estrella MM, Shlipak MG, et al. Patient awareness of CKD: a systematic review and meta-analysis of patient-oriented questions and study setting. Kidney Med 2021;3:576-85.e1.
Ene-Iordache B, Perico N, Bikbov B, Carminati S, Remuzzi A, Perna A, et al. Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): a cross-sectional study. Lancet Global Health 2016;4:e307-19.
Gummidi B, John O, Ghosh A, Modi GK, Sehgal M, Kalra OP, et al. A systematic study of the prevalence and risk factors of CKD in Uddanam, India. Kidney Int Rep 2020;5:2246-55.
Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int 2022;102:S1-127.
Nicholas SB, Daratha KB, Alicic RZ, Jones CR, Kornowske LM, Neumiller JJ, et al. Prescription of guideline-directed medical therapies in patients with diabetes and chronic kidney disease from the CURE-CKD Registry, 2019-2020. Diabetes Obes Metab 2023;25:2970-9.
Grams ME, Yang W, Rebholz CM, Wang X, Porter AC, Inker LA, et al. Risks of adverse events in advanced CKD: The Chronic Renal Insufficiency Cohort (CRIC) study. Am J Kidney Dis 2017;70:337-46.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 2024;105:S117-314.
Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int 2021;99:S1-87.
Tuttle KR, Alicic RZ, Duru OK, Jones CR, Daratha KB, Nicholas SB, et al. Clinical characteristics of and risk factors for chronic kidney disease among adults and children: an analysis of the CURE-CKD registry. JAMA Netw Open 2019;2:e1918169.
Ismail WW, Witry MJ, Urmie JM. The association between cost sharing, prior authorization, and specialty drug utilization: a systematic review. J Manag Care Spec Pharm 2023;29:449-63.
Heerspink HJL, Vart P, Jongs N, Neuen B, Bakris G, Claggett B, et al. Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: a joint analysis of randomized controlled clinical trials. Diabetes Obes Metab 2023;25:3327-36.
Nuffield Department of Population Health Renal Studies Group. SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet 2022 ;400:1788-801.
Fernández-Fernandez B, Sarafidis P, Soler MJ, Ortiz A. EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors. Clin Kidney J 2023;16:1187-98.
McEwan P, Boyce R, Sanchez JJG, Sjöström CD, Stefansson B, Nolan S, et al. Extrapolated longer-term effects of the DAPA-CKD trial: a modelling analysis. Nephrol Dial Transplant 2023;38:1260-70.
Vanholder R, Annemans L, Braks M, Brown EA, Pais P, Purnell TS, et al. Inequities in kidney health and kidney care. Nat Rev Nephrol 2023;19:694-708.
Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joeph A, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J 2022;43:474-84.
Tuttle KR, Bosch-Traberg H, Cherney DZI, Hadjadj S, Lawson J, Mosenzon O, et al. Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo. Kidney Int 2023;103:772-81.
Rubin R. It takes an average of 17 years for evidence to change practice-the burgeoning field of implementation science seeks to speed things up. JAMA 2023;329:1333-6.
World Health Organisation. Mid-point evaluation of the implementation of the WHO global action plan for the prevention and control of noncommunicable diseases 2013–2020 (NCD-GAP) [Internet]. [cited 2023 Nov 18]. Available from: https://cdn.who.int/ media/docs/default-source/documents/about-us/ evaluation/ncd-gap-final-report.pdf?sfvrsn=55b-22b89_5&download=true
Kruk ME, Gage AD, Joseph NT, Danaei G, García-Saisó S, Salomon J. Mortality due to low-quality health systems in the universal health coverage era: a systematic analysis of amenable deaths in 137 countries. Lancet 2018;392 :2203-12.
Kingori P, Grietens KP, Abimbola S, Ravinetto R. Uncertainties about the quality of medical products globally: lessons from multidisciplinary research. BMJ Glob Health 2023;6:e012902.
Pan American Health Organization Quality control of medicines [Internet]. [cited 2023 Nov 18]. Available from: https://www.paho.org/en/topics/quality-control-medicines
Tuttle KR, Wong L, St Peter W, Roberts G, Ran- gaswami J, Mottl A, et al. Moving from evidence to implementation of breakthrough therapies for diabetic kidney disease. Clin J Am Soc Nephrol 2022;17:1092-103.
Kalyesubula R, Conroy AL, Calice-Silva V, Kumar V, Onu U, Batte A, et al. Screening for kidney disease in low- and middle-income countries. Semin Nephrol 2022;42:151315.
Francis A, Hafidz MIA, Ekrikpo UE, Chen T, Wijewickrama E, Tannor EK, et al. Barriers to accessing essential medicines for kidney disease in low- and lower middle-income countries. Kidney Int 2022;102:969-73.
Rangaswami J, Tuttle K, Vaduganathan M. Cardio-renal-metabolic care models: toward achieving effective interdisciplinary care. Circ Cardiovasc Qual Outcomes 2020;13:e007264.
Neumiller JJ, Alicic RZ, Tuttle KR. Overcoming barriers to implementing new therapies for diabetic kidney disease: lessons learned. Adv Chronic Kidney Dis 2021;28:318-27.
Mishra SR, Neupane D, Preen D, et al. Mitigation of non-communicable diseases in developing countries with community health workers. Global Health 2015:11:43.
Joshi R, John O, Jha V. The potential impact of public health interventions in preventing kidney disease. Semin Nephrol 2017;37:234-44.
Patel A, Praveen D, Maharani A, Oceandy D, Pilard Q, Kohli MP, et al. Association of multifaceted mobile technology-enabled primary care intervention with cardiovascular disease risk management inrural Indonesia. JAMA Cardiol 2019 ;4:978-86.
Ardavani A, Curtis F, Khunti K, Wilkinson T. The effect of pharmacist-led interventions on the management and outcomes in chronic kidney disease (CKD): a systematic review and meta-analysis protocol. Health Sci Rep 2023;6:e1064.
Sherrod CF, Farr SL, Sauer AJ. Overcoming treatment inertia for patients with heart failure: how do we build systems that move us from rest to motion? Eur Heart J 2023;44:1970-2.
Ramakrishnan C, Tan NC, Yoon S, Hwang SJ, Foo MWY, Paulpandi M, et al. Healthcare professionals’ perspectives on facilitators of and barriers to CKD management in primary care: a qualitative study in Singapore clinics. BMC Health Services Res 2022;22:560.
Porter J, Boyd C, Skandari MR, Laiteerapong. Revisiting the time needed to provide adult primary care. J Gen Intern Med 2023;38:147-55.
Peralta CA, Livaudais-Toman J, Stebbins M, Lo L, Robinson A, Pathak S, et al. Electronic decision support for management of CKD in primary care: a pragmatic randomized trial. Am J Kidney Dis 2020; 76:636-44.
Rios P, Sola L, Ferreiro A, Silvarño R, Lamadrid V, Ceretta L, et al. Adherence to multidisciplinary care in a prospective chronic kidney disease cohort is associated with better outcomes. PLoS One 2022;17:e0266617.
Stevenson JK, Campbell ZC, Webster AC, Chow CK, Tong A, Craig JC, et al. eHealth interventions for people with chronic kidney disease. Cochrane Database Syst Rev 2019;8:CD012379.
Tuot DS, Crowley ST, Katz LA, Leung J, Alcantara-Cadillo DK, Ruser C, et al. Usability testing of the kidney score platform to enhance communication about kidney disease in primary care settings: qualitative think-aloud study. JMIR Form Res 2022;6:e40001.
Verberne WR, Stiggelbout AM, Bos WJW, Delden JJM. Asking the right questions: towards a person-centered conception of shared decision-making regarding treatment of advanced chronic kidney disease in older patients. BMC Med Ethics 2022;23:47.
Taha A, Iman Y, Hingwala J, Askin N, Mysore P, Rigatto C, et al. Patient navigators for CKD and kidney failure: a systematic review. Kidney Med 2022;4:100540.
Essue BM, Laba M, Knaul F, Chu A, Minh HV, Nguyen TKP, et al. Economic burden of chronic ill health and injuries for households in low- and middle-income countries. In: Jamison DT, Gelband H, Horton S, Jha P, Laxminarayan R, Mock CN, et al, editors. Disease Control Priorities: Improving Health and Reducing Poverty. 3rd ed. The International Bank for Reconstruction and Development/ The World Bank; 2017.
Khatib K, McKee M, Shannon H, Chow C, Rangarajan S, Teo K, et al. Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data. Lancet 2016;387:61-9.
Kamath N, Iyengar AA. Chronic kidney disease (CKD): an observational study of etiology, severity and burden of comorbidities. Indian J Pediatr 2017;84:822-5.
Cirillo L, Ravaglia F, Errichiello C, Anders HJ, Ro- magnani P, Becherucci F. Expectations in children with glomerular diseases from SGLT2 inhibitors. Pediatr Nephrol 2022;37:2997-3008.
Donohue JF, Elborn JS, Lansberg P, Javed A, Tesfaye S, Rugo H, et al. Bridging the “know-do” gaps in five non-communicable diseases using a common framework driven by implementation science. J Healthc Leadersh 2023;15:103-9.
Population Health Research Institute. Polypills added to WHO essential medicines list [Internet]. [cited 2023 Nov 18]. Available from: https://www. phri.ca/eml/
Sepanlou SG, Mann JFE, Joseph P, Pais P, Gao P, Sharafkhah M, et al. Fixed-dose combination therapy for prevention of cardiovascular diseases in CKD: an individual participant data meta-analysis. Clin J Am Soc Nephrol 2023;18:1408-15.
Dev V, Mittal A, Joshi V, Meena JK, Goel AD, Didel S, et al. Cost analysis of telemedicine use in paediatric nephrology-the LMIC perspective. Pediatr Nephrol 2024;39:193-201.
Musacchio N, Zilich R, Ponzani P, Guaita G, Giorda C, Heidbreder R, et al. Transparent machine learning suggests a key driver in the decision to start insulin therapy in individuals with type 2 diabetes. J Diabetes 2023;15:224-36.
Zuniga C, Riquelme C, Muller H, Vergara G, Astorga C, Espinoza M. Using telenephrology to improve access to nephrologist and global kidney management of CKD primary care patients. Kidney Int Rep 2020;5:920-3.
van der Horst DEM, Hofstra N, van Uden-Kraan CF, Stiggelbout AM, van den Dorpel M, Pieterse AH, et al. Shared decision making in health care visits for CKD: patients’ decisional role preferences and experiences. Am J Kidney Dis 2023;82:677-86.
Hole B, Scanlon M, Tomson C. Shared decision making: a personal view from two kidney doctors and a patient. Clin Kidney J 2023;16:i12-9.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Insight Urology

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.